Furthermore, their study evidenced that the early surge in CX3CR1+ subset frequency among circulating CD8+ T cells was correlated to both responses by and prolonged survival of non-small cell lung cancer patients undergoing anti-PD-1 therapy. The gene discussed is CX3CR1; the disease is non-small cell lung carcinoma.